Basecare's innovative technology helps couples who have experienced repeated miscarriages to select healthy,chromosomally-normal embryos to implant during IVF
PGH technology is the upgrading of third generation IVF technology, which can block the transmission of structural abnormalities, such as chromosomal balanced translocation, to the next generation.
In August 2017, a couple went to the Suzhou municipal hospital for treatment. The wife experienced repeated miscarriages after marriage. After examination, the woman was found to have translocation of chromosome 7 and chromosome 11. The woman may need to experience repeated miscarriage to get a healthy baby if she want to conceive naturally. Theoretically, without the help of assisted reproductive technology, the couples only have a 1/9 chance of having a normal baby. In order to completely block the transmission of balanced translocation to the offspring, the couple decided to use the “third-generation” test-tube baby technique to conceive a child. Suzhou municipal Hospital uses PGH technology to assess and diagnose problems in the genetic makeup of embryos, and helped the couple select normal embryos for implantation, the woman finally gives birth to a healthy baby.
Chromosomal balanced translocation is a common chromosomal structural variation in human beings. One couple in 150 couples are the carrier of this structural variation. In couples with recurrent abortion (the number of abortions ≥ 3), the incidence of this variation is nearly 30 times higher than that of ordinary people. There is no difference in phenotype between balanced translocation carriers and ordinary people, but the probability of having healthy offspring in this population is only 1/9, most of the rest are at risk of miscarriage, embryo termination or birth defects. Even if they are lucky enough, their offspring will still have a 50% chance of inheriting the same mutation. After these offspring grows up, they will face the same fertility problem with their parents, which is the reason why two generations of the Suzhou family suffered from the curse of repeated abortion.
According to statistics, there are about 8000000IVF cycles in China every year, and the proportion of recurrent miscarriage caused by balanced translocation is about 8%, that is, there are 64000 IVF cycles, nearly 500000 embryos need to be distinguished. With the increasing number of infertile people year by year, the medical demand for the technical solution of recurrent abortion will continue to expand. According to 5500 yuan per embryo, the industrial scale of this market segment is expected to reach 3 billion yuan in the next three to five years.
As a leading enterprise in reproductive health, under the strong support of Suzhou municipal government, Basecare has been adhering to the “two legs” development strategy of core technology research and development and scientific research achievements transformation. The company has a GMP production workshop of 1500 square meters and a research and development laboratory of nearly 3000 square meters, and has created a perfect platform for scientific research transformation, which is equipped with the basic conditions for the rapid industrialization of excellent scientific research achievements. The core technology to break the "recurrent abortion curse" is also developed on this platform.
In February 2020, the PGT-A kit independently developed by Basecare won the first medical device registration certificate in the industry (Approval No.: 20203400181), and the company was awarded "Suzhou Unicorn breeding enterprise" in June. In the future, Basecare will continue to make efforts on innovative technology research and development and industrialization, so as to promote local enterprises in Suzhou to better serve local citizens and help more families to have healthy baby.